Auspherix Appoints Neil Miller CSO
This article was originally published in Scrip
Auspherix Ltd. has appointed Dr Neil Miller chief scientific officer (CSO) replacing co-founder and previously consultant CSO Professor Ian Charles, who will continue to contribute to the company as board member and chair of the scientific advisory board. Miller joins Auspherix from GlaxoSmithKline PLC., where he spent two decades, most recently as senior director and head of chemistry, DMPK and external discovery in Singapore. He held various other managerial and scientific roles at GSK including site head at GSK's R&D centre in Singapore.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.